The invention relates to the field of medicine. Among others it relates to biologically active analogs of interferons (IFNs) which show less unwanted side effects and to the therapeutic uses thereof. Provided is an IFN analog wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity said signaling moiety being provided at its N terminus optionally via a linker with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.
